FUNCTIONAL AND HISTOLOGICAL CONSEQUENCES OF QUINOLINIC AND KAINIC ACID-INDUCED SEIZURES ON HIPPOCAMPAL SOMATOSTATIN NEURONS

被引:37
作者
MANFRIDI, A [1 ]
FORLONI, GL [1 ]
VEZZANI, A [1 ]
FODRITTO, F [1 ]
DESIMONI, MG [1 ]
机构
[1] MARIO NEGRI INST PHARMACOL RES,VIA ERITREA 62,I-20157 MILAN,ITALY
关键词
D O I
10.1016/0306-4522(91)90203-Z
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Changes in endogenous somatostatin after quinolinic and kainic acids were investigated by measuring somatostatin-like peaks by in vivo voltammetry and by assessing the distribution of somatostatin-positive neurons by immunocytochemistry. Kainic acid (0.19 nmol/0.5-mu-l) or quinolinic acid (120 nmol/0.5-mu-l) in doses inducing comparable electroencephalographic seizure patterns, were injected into the hippocampus of freely moving rats. Somatostatin-like peaks were measured every 6 min for 3 h by a carbon fiber electrode implanted in the proximity of the injection needle. Kainic acid kept somatostatin-like peaks significantly higher than saline from 48 min after the injection till the end of the recording. Somatostatin-like peaks were dramatically elevated by quinolinic acid, reaching a maximum of 482% 60 min after the injection. Three days later, administration of kainic acid resulted in selective degeneration of CA3 pyramidal neurons but did not affect the number of somatostatin-positive cells, while quinolinic acid induced cell loss in all pyramidal layers and complete degeneration of somatostatin-positive cells in the whole hippocampus. Thus, the quantitative difference in somatostatin release in response to doses of kainic and quinolinic acids inducing comparable electroencephalographic seizure patterns was reflected in a substantial difference in the neurodegenerative consequences. In both models, the release of somatostatin in response to seizures may be interpreted as a "defense" mechanism aimed at reducing the spread of excitation in the tissue.
引用
收藏
页码:127 / 135
页数:9
相关论文
共 43 条
[1]   SOMATOSTATIN IS INCREASED IN THE BASAL GANGLIA IN HUNTINGTON DISEASE [J].
ARONIN, N ;
COOPER, PE ;
LORENZ, LJ ;
BIRD, ED ;
SAGAR, SM ;
LEEMAN, SE ;
MARTIN, JB .
ANNALS OF NEUROLOGY, 1983, 13 (05) :519-526
[2]  
BAKHIT C, 1983, NATURE, V301, P324
[3]   DEPLETION OF STRIATAL SOMATOSTATIN BY LOCAL CYSTEAMINE INJECTION [J].
BEAL, MF ;
MARTIN, JB .
BRAIN RESEARCH, 1984, 308 (02) :319-324
[4]   REPLICATION OF THE NEUROCHEMICAL CHARACTERISTICS OF HUNTINGTONS-DISEASE BY QUINOLINIC ACID [J].
BEAL, MF ;
KOWALL, NW ;
ELLISON, DW ;
MAZUREK, MF ;
SWARTZ, KJ ;
MARTIN, JB .
NATURE, 1986, 321 (6066) :168-171
[6]   ELECTROCHEMISTRY OF NEUROPEPTIDES - A POSSIBLE METHOD FOR ASSAY AND INVIVO DETECTION [J].
BENNETT, GW ;
BRAZELL, MP ;
MARSDEN, CA .
LIFE SCIENCES, 1981, 29 (10) :1001-1007
[7]   HYPOTHALAMIC POLYPEPTIDE THAT INHIBITS SECRETION OF IMMUNOREACTIVE PITUITARY GROWTH-HORMONE [J].
BRAZEAU, P ;
VALE, W ;
BURGUS, R ;
LING, N ;
BUTCHER, M ;
RIVIER, J ;
GUILLEMIN, R .
SCIENCE, 1973, 179 (4068) :77-79
[8]  
CRESPI F, 1987, British Journal of Pharmacology, V92, p696P
[9]   REDUCED SOMATOSTATIN-LIKE IMMUNOREACTIVITY IN CEREBRAL-CORTEX FROM CASES OF ALZHEIMER-DISEASE AND ALZHEIMER SENILE DEMENTIA [J].
DAVIES, P ;
KATZMAN, R ;
TERRY, RD .
NATURE, 1980, 288 (5788) :279-280
[10]   HIPPOCAMPAL INTERNEURON LOSS AND PLASTICITY IN HUMAN TEMPORAL-LOBE EPILEPSY [J].
DELANEROLLE, NC ;
KIM, JH ;
ROBBINS, RJ ;
SPENCER, DD .
BRAIN RESEARCH, 1989, 495 (02) :387-395